PMID- 31452140
OWN - NLM
STAT- MEDLINE
DCOM- 20190917
LR  - 20190917
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1158
DP  - 2019
TI  - Investigating the Role of Mitochondria in Type 2 Diabetes - Lessons from 
      Lipidomics and Proteomics Studies of Skeletal Muscle and Liver.
PG  - 143-182
LID - 10.1007/978-981-13-8367-0_9 [doi]
AB  - Mitochondrial dysfunction is discussed as a key player in the pathogenesis of 
      type 2 diabetes mellitus (T2Dm), a highly prevalent disease rapidly developing as 
      one of the greatest global health challenges of this century. Data however about 
      the involvement of mitochondria, central hubs in bioenergetic processes, in the 
      disease development are still controversial. Lipid and protein homeostasis are 
      under intense discussion to be crucial for proper mitochondrial function. 
      Consequently proteomics and lipidomics analyses might help to understand how 
      molecular changes in mitochondria translate to alterations in energy transduction 
      as observed in the healthy and metabolic diseases such as T2Dm and other related 
      disorders. Mitochondrial lipids integrated in a tool covering proteomic and 
      functional analyses were up to now rarely investigated, although mitochondrial 
      lipids might provide a possible lynchpin in the understanding of type 2 diabetes 
      development and thereby prevention. In this chapter state-of-the-art analytical 
      strategies, pre-analytical aspects, potential pitfalls as well as current 
      proteomics and lipidomics-based knowledge about the pathophysiological role of 
      mitochondria in the pathogenesis of type 2 diabetes will be discussed.
FAU - Kappler, Lisa
AU  - Kappler L
AD  - Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic 
      Laboratory Medicine, University Hospital Tuebingen, Tuebingen, Germany.
FAU - Kollipara, Laxmikanth
AU  - Kollipara L
AD  - Leibniz-Institut fur Analytische Wissenschaften - ISAS - e.V., Dortmund, Germany.
FAU - Lehmann, Rainer
AU  - Lehmann R
AD  - Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic 
      Laboratory Medicine, University Hospital Tuebingen, Tuebingen, Germany.
AD  - Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre 
      Munich at the University of Tuebingen, Tuebingen, Germany.
AD  - German Center for Diabetes Research (DZD e.V.), Tuebingen, Germany.
FAU - Sickmann, Albert
AU  - Sickmann A
AD  - Leibniz-Institut fur Analytische Wissenschaften - ISAS - e.V., Dortmund, Germany. 
      sickmann@isas.de.
AD  - Medical Proteome Centre, Ruhr Universitat Bochum, Bochum, Germany. 
      sickmann@isas.de.
AD  - Department of Chemistry, College of Physical Sciences, University of Aberdeen, 
      Aberdeen, UK. sickmann@isas.de.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
SB  - IM
MH  - *Computational Biology
MH  - *Diabetes Mellitus, Type 2/physiopathology
MH  - Humans
MH  - Lipid Metabolism
MH  - *Liver/physiopathology
MH  - *Mitochondria/metabolism
MH  - *Muscle, Skeletal/physiopathology
MH  - *Proteomics
OTO - NOTNLM
OT  - Function
OT  - Lipidomics
OT  - Mass spectrometry
OT  - Mitochondria
OT  - Proteomics
OT  - Type 2 diabetes
EDAT- 2019/08/28 06:00
MHDA- 2019/09/19 06:00
CRDT- 2019/08/28 06:00
PHST- 2019/08/28 06:00 [entrez]
PHST- 2019/08/28 06:00 [pubmed]
PHST- 2019/09/19 06:00 [medline]
AID - 10.1007/978-981-13-8367-0_9 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2019;1158:143-182. doi: 10.1007/978-981-13-8367-0_9.